Tripokin is a fully-human immunostimulatory product consisting of tumor necrosis factor (TNF) and interleukin-2 (IL2) fused into one molecular entity.

TNF induces a rapid hemorrhagic tumor necrosis, while IL2 stimulates cancer-specific immune effector cells, when delivered to the site of disease.  The fusion to the L19 antibody, which is specific to the EDB domain of fibronectin, generates a tumor targeted product that selectively localizes at the site of disease, while sparing healthy organs.

Tripokin capitalizes of the synergistic mechanism of action of TNF and IL2 . The products has shown a strong anti-tumor activity as single agent in various preclinical models of cancer. Tripokin exhibits excellent tumor-homing properties and the most potent activity ever reported for IL2-based therapeutics. These best-in-class therapeutic properties can be further potentiated by combination therapies with immune check-point inhibitors.

Tripokin is the next biotherapeutic candidate that Philogen aims to bring to the clinic.



De Luca et al.(2019) Frontiers in Oncology, 9, 1228

De Luca et al. (2018) Cancer Immunology Immunotherapy, 67, 1381-91

De Luca et al. (2017) Mol Cancer Ther, 16, 2442-51

Schwager et al. (2013) J Invest Dermatol, 133, 751-8